These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 35277357)

  • 21. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.
    Sergeev V; Chou FY; Lam GY; Hamilton CM; Wilcox PG; Quon BS
    Ann Am Thorac Soc; 2020 Feb; 17(2):147-154. PubMed ID: 31661636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators.
    Kramer-Golinkoff E; Camacho A; Kramer L; Taylor-Cousar JL
    Pediatr Pulmonol; 2022 May; 57(5):1253-1261. PubMed ID: 35170259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of disease-causing CFTR variants in state newborn screening programs.
    McGarry ME; Ren CL; Wu R; Farrell PM; McColley SA
    Pediatr Pulmonol; 2023 Feb; 58(2):465-474. PubMed ID: 36237137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
    Bell SC; De Boeck K; Amaral MD
    Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small-molecule drugs for cystic fibrosis: Where are we now?
    Laselva O; Guerra L; Castellani S; Favia M; Di Gioia S; Conese M
    Pulm Pharmacol Ther; 2022 Feb; 72():102098. PubMed ID: 34793977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum.
    Habler K; Kalla AS; Rychlik M; Bruegel M; Teupser D; Nährig S; Vogeser M; Paal M
    Clin Chem Lab Med; 2022 Jan; 60(1):82-91. PubMed ID: 34668357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators.
    Fajac I; Sermet-Gaudelus I
    Curr Opin Pulm Med; 2021 Nov; 27(6):567-574. PubMed ID: 34494979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Global disparities in cystic fibrosis outcomes prior to CFTR modulators: A CF registries cohort study in South Africa and Canada.
    Zampoli M; Sykes J; Verstraete J; Cheng SY; Morrow B; Pepper MS; Stewart C; Zar HJ; Stephenson AL
    J Cyst Fibros; 2024 Mar; 23(2):334-340. PubMed ID: 37704465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.
    O'Reilly R; Elphick HE
    Drug Des Devel Ther; 2013; 7():929-37. PubMed ID: 24039402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cystic fibrosis: candidate selection and impact of the cystic fibrosis transmembrane conductance regulator therapy.
    Lehr CJ; Pilewski JM
    Curr Opin Organ Transplant; 2022 Jun; 27(3):198-203. PubMed ID: 35184094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis.
    Costa E; Girotti S; Pauro F; Leufkens HGM; Cipolli M
    Orphanet J Rare Dis; 2022 May; 17(1):188. PubMed ID: 35525974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
    Lin S; Sui J; Cotard S; Fung B; Andersen J; Zhu P; El Messadi N; Lehar J; Lee M; Staunton J
    Assay Drug Dev Technol; 2010 Dec; 8(6):669-84. PubMed ID: 21050065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.
    Kotha K; Clancy JP
    Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France.
    Regard L; Martin C; Burnet E; Da Silva J; Burgel PR
    Cells; 2022 May; 11(11):. PubMed ID: 35681464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis.
    Harvey C; Weldon S; Elborn S; Downey DG; Taggart C
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of CFTR modulators for the treatment of cystic fibrosis.
    Lopes-Pacheco M; Pedemonte N; Veit G
    Expert Opin Drug Discov; 2021 Aug; 16(8):897-913. PubMed ID: 33823716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis.
    Taylor-Cousar JL; Shteinberg M; Cohen-Cymberknoh M; Jain R
    Clin Ther; 2023 Mar; 45(3):278-289. PubMed ID: 36841738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.